Uniphar PLC is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Uniphar PLC in the market include companies like McKesson, AmerisourceBergen, and Cardinal Health. These companies operate in the same industry as Uniphar, providing pharmaceutical and healthcare distribution services. Other competitors that Uniphar faces in specific segments of its business include Sisk Healthcare, United Drug, and DCC Healthcare. Uniphar PLC competes with these industry players to gain market share and maintain its position in the healthcare and pharmaceutical distribution sector.

Uniphar PLC is a leading healthcare services provider based in Ireland. Established in 1967, the company has a rich history of over 50 years. Initially a wholesale pharmaceutical business, Uniphar expanded its operations to include integrated commercial and clinical services. Today, it offers a comprehensive range of services to the healthcare industry, including supply chain management, retail pharmacy, product licensing, and support services. Uniphar has a strong presence in Ireland and the UK, and its diverse customer base includes hospitals, pharmacies, pharmaceutical manufacturers, and the government. The company's commitment to innovation, reliability, and customer satisfaction has propelled it to become a trusted partner in the healthcare sector.

Some significant milestones achieved by Uniphar PLC include its successful listing on the Euronext Dublin and London Stock Exchanges in July 2019, marking a significant step in its growth and expansion plans. The company has also made strategic acquisitions, such as the acquisition of M3 Medical Limited in 2020, which strengthened its position in the Irish healthcare market. Furthermore, Uniphar PLC has consistently delivered strong financial performance, with revenue and profit growth year after year. Its focus on innovation and developing new capabilities has allowed the company to enhance its offering and provide comprehensive solutions to the healthcare industry.

Uniphar PLC is primarily present in Ireland, the United Kingdom, and the Benelux region. This pharmaceutical and healthcare services company operates across these countries, providing a wide range of services to healthcare providers, manufacturers, and patients. Uniphar PLC's strong presence in these regions allows them to leverage their expertise and network for the benefit of their customers.

Uniphar PLC represents values of integrity, collaboration, innovation, and customer-focus. With a strong corporate philosophy centered around delivering excellence in healthcare, Uniphar is committed to providing high-quality products and services to improve patient outcomes. The company places great emphasis on building trusted partnerships with healthcare professionals and industry stakeholders, enabling them to navigate complex healthcare supply chains effectively. Uniphar's dedication to continuous innovation and adaptability in a rapidly evolving industry sets it apart. By prioritizing customer needs and maintaining a steadfast focus on ethical practices, Uniphar PLC has established itself as a leading player in the healthcare sector.

Analysts currently set an average price target of 4,93 EUR for the Uniphar stock (median: 4,94 EUR), implying +14,9 % versus the latest price. The consensus is based on 12 analyst ratings.

Uniphar Analyytikkojen kursstavoitteet 2026

12 analysts currently rate the Uniphar stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Uniphar to generate revenue of 3,21 Mrd. EUR and earnings per share of 0,28 EUR.

Uniphar Analyytikkojen kursstavoitteet 2026

The Uniphar share (UPR.IR) is listed on 4 stock exchanges, including: Frankfurt (0NR.F), München (0NR.MU), London (UPR.L), London (UPR.L).

Uniphar PLC is a leading provider of healthcare solutions and pharmaceutical products in Europe. The company offers a wide range of services and products that meet the medical needs of patients. Uniphar was founded in 1994 and has been a publicly listed company since 2019. The business model of Uniphar is focused on offering a comprehensive range of services and products in various areas of healthcare. The company has different divisions tailored to the needs of its customers. The division "Uniphar Retail Services" specializes in wholesale and retail. The division offers a wide range of retail products, including over-the-counter medications, dietary supplements, medical devices, and cosmetics. Uniphar also works closely with retailers to develop customized solutions for their needs. Uniphar also has a division called "Uniphar Group" that specializes in providing pharmaceutical products to hospitals and clinics. In addition, the division also offers solutions for drug manufacturing and delivery. Through close collaboration with the pharmaceutical industry, the company also offers solutions for the trade of pharmaceutical products. The division "Uniphar Specialty Healthcare" specializes in the distribution of specialized drugs. The company offers a wide range of medical products for the treatment of chronic conditions such as diabetes, cancer, and HIV/AIDS. The division also works closely with healthcare professionals and hospitals to ensure that patients receive the right medications. Uniphar has also developed a digital platform called "Uniphar Connect". This platform allows customers and business partners to access a wide range of products and services offered by Uniphar. The platform also provides efficient order and delivery processing to ensure that customers receive their required products quickly and easily. Overall, Uniphar has a diversified product portfolio and offers a comprehensive range of services tailored to the needs of the healthcare industry. The company has a strong presence in Europe and works closely with its customers and partners to develop customized solutions for their needs. With a strong focus on digital innovation and strategic partnerships, the company is well positioned to be successful in the future.

odotettu liikevaihto Uniphar on 3,21 Mrd. EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Uniphar on 71,88 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Uniphar:n hinta-voitto-suhde (P/E) on tällä hetkellä 15,49. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Uniphar-osakkeen arvostusta.

Uniphar:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,35. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Uniphar-osakkeen arvostuskennuslukuna.

Uniphar:n Eulpool-laatuscore on 6/10.

Uniphar:n ISIN on IE00BJ5FQX74. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Uniphar:n WKN on A2PNWJ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Uniphar:n ticker on UPR.IR. Tämä pörssinoteeraus käytetään Uniphar-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Uniphar maksoi osinkoa 0,02 EUR . Tämä vastaa osingontuottoa noin 0,46 %. Tulevien 12 kuukauden aikana Uniphar odotetaan maksavan osinkoa 0,03 EUR.

Uniphar:n nykyinen osinkotuotto on 0,46 %.

Uniphar maksaa osinkoa, joka jaetaan kuukausina , , , .

Uniphar maksoi osinkoa joka vuosi viimeisten 6 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 0,03 EUR. Tämä vastaa osingontuottoa 0,66 %.

Uniphar kuuluu sektoriin 'Terveydenhuolto'.

Saadaksesi viimeisen osingon Uniphar:sta päivältä määrässä 0,01 EUR, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Vuonna 2025 Uniphar jakoi 0,02 EUR osinkona.

Uniphar:n osingot jaetaan valuutassa EUR.